Comparative Pharmacology
Head-to-head clinical analysis: SEZABY versus ZYPREXA RELPREVV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEZABY versus ZYPREXA RELPREVV.
SEZABY vs ZYPREXA RELPREVV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission.
Olanzapine pamoate is a second-generation antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also binds to adrenergic α1, histamine H1, and muscarinic M1 receptors.
58 mg subcutaneously once monthly (every 30 days).
210 mg intramuscular injection every 2 weeks; range 150-300 mg; max 300 mg per dose. For olanzapine-naive patients, establish tolerability with oral olanzapine before initiation.
None Documented
None Documented
The terminal elimination half-life of Sezaby is approximately 24 hours in healthy adults. This supports once-daily dosing. In patients with hepatic impairment, half-life may be prolonged.
The terminal elimination half-life ranges from 30 to 60 days (mean ~45 days) after intramuscular injection, consistent with extended release from the depot formulation.
Sezaby undergoes extensive hepatic metabolism, with approximately 75% of the dose excreted in feces as metabolites and 20% in urine as unchanged drug and metabolites. Renal clearance accounts for less than 5% of total clearance.
Approximately 57% of the dose is excreted in urine (30% as unchanged drug, 27% as metabolites) and 30% in feces (primarily as metabolites).
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic